Infections and atherosclerosis

Scandinavian Cardiovascular Journal

Volumn 34, Issue 1, 2000, Pages 12-20

  Leinonen, Maija ^a   Saikku, Pekka ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NONE

Author keywords

Acute myocardial infarction; Atherosclerosis; Chlamydia pneumoniae; Coronary heart disease; Infections; Intervention; Pathogenetic mechanism

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; ROXITHROMYCIN;

ATHEROSCLEROSIS; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CYTOMEGALOVIRUS; HELICOBACTER PYLORI; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HUMAN; INFECTION; INFLAMMATION; ISCHEMIC HEART DISEASE; META ANALYSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RESTENOSIS; REVIEW; SEROEPIDEMIOLOGY; TOOTH INFECTION; VIRUS INFECTION;

EID: 0034036757     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430050142341     Document Type: Review

References (118)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for future research. Circulation 1997; 96: 4095-4103.
3. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population-based cross-sectional study. Br Med J 1996; 312: 1061-1065.
4. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.
5. Anderson JL, Carlquist JF, Muhlestein JB, Home BD, Elmer SP. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998; 32: 35-41.
6. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-860.
7. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-436.
8. Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998; 26: 719-734.
9. Nieto FJ. Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol 1998; 148: 937-948.
10. Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol 1984; 53: 481-482.
11. Mattila KJ. Viral and bacterial infections in patients with acute myocardial infarction. J Intern Med 1989; 225: 293-296.
12. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory tract infections and risk of first-time acute myocardial infarction. Lancet 1998; 351: 1467-1471.
13. Blasi F, Consentini R, Raccanelli R, et al. A possible association of Chlamydia pneumoniae infection and acute myocardial infarction in patients younger than 65 years of age. Chest 1997; 112: 309-312.
14. Sessa R, DiPietro M, Santino I, et al. Chlamydia pneumoniae infection and athrosclerotic coronary disease. Am Heart J 1999; 137: 1116-1119.
15. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999; 281: 427-431.
16. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline or doxycycline. Emerg Infect Dis 1999; 5: 281-284.
17. Woodruff JF. Viral myocarditis. A review. Am J Pathol 1980; 101: 425-484.
18. Sohal RS, Burch GE, Chu KC, Leiderman E, Colcolough HL. Ultrastructural changes in cardiac capillaries of coxsackie virus b4-infected mice. Lab Invest 1968; 19: 399-405.
19. Griffiths PD, Hannington G, Booth JC. Coxsackie B virus infections and myocardial infarction. Lancet 1980; 1: 1387-1389.
20. Roivainen M, Alfthan G, Jousilahti P, Kimpimäki M, Hovi T, Tuomilehto J. Enterovirus infections as a possible risk factor for myocardial infarction. Circulation 1998; 98: 2534-2537.
21. Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Atherosclerosis induced by infection with a herpes virus. Am J Pathol 1981; 105: 176-184.
22. Fabricant CG, Fabricant J, Minick CR, Litrenta MM. Herpesvirus-induced atherosclerosis in chickens. Fed Proc 1983; 42: 2476-2479.
23. Siscovick DS, Scwartz SM, Corey L, et al. Antibody to Chlamydia pneumoniae, herpes simplex virus type 1, cytomegalovirus and incident myocardial infarction and coronary heart disease death (Abstr.). Circulation 1998; 97: 814.
24. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624-630.
25. Gyorkey F, Melnick JL, Guinn GA, Gyorkey P, DeBakey ME. Herpes viridae in the endothelial and smooth muscle cells of the proximal aorta of atherosclerotic patients. Exp Mol Pathol 1984; 40: 328-339.
26. Yamashiroya HM, Ghosh L, Yang R, Robertson AL. Herpes viridae in the coronary arteries and aorta of young trauma victims. Am J Pathol 1988; 130: 71-79.
27. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomagalovirus, and herpes complex virus in atherosclerosis of the carotid artery. Circulation 1997; 96: 2144-2148.
28. Wald NJ, Law MR, Morris JK, Bagnall AM. Helicobacter pylori infection and mortality from ischaemic heart disease: negative results from a large, prospective study. Br Med J 1997; 315: 1199-1201.
29. Pasceri V, Cammarota G, Maseri A. Association of virulent Helicobacter pylori strains with ischaemic heart disease. Circulation 1998; 97: 1738-1742.
30. Malnick SDH, Goland S, Kaftoury A, et al. Evaluation of carotid arterial plaques after endarterectomy for Helicobacter pylori infection. Am J Cardiol 1999; 83: 1586.
31. Blasi F, Denti F, Erba M, et al. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of abdominal aorticaneurysms. J Clin Microbiol 1996; 34: 2766-2769.
32. Niemelä S, Karttunen T, Korhonen T, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations. Heart 1995; 75: 573-575.
33. Laurila AL, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999; 142: 207-210.
34. Mattila KJ, Nieminen MS, Valtonen VV, et al. Association between dental health and acute myocardial infarction. Br Med J 1989; 298: 779-781.
35. DeStefano F, Anda RF, Kahn HS, Williamson DF, Russel CM. Dental disease and risk of new coronary heart disease and mortality. Br Med J 1993; 306: 688-691.
36. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618-625.
37. Hahn DL, Dodge RW, Golubjatnikov R. Association of Chlamydia pneumoniae infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 1991; 266: 225-230.
38. von Hertzen L, Alakärppä H, Koskinen R, et al. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect 1997; 118: 155-164.
39. Laurila AL, Anttila T, Läärä E, et al. Serologic evidence of an association of chronic Chlamydia pneumoniae infection with lung cancer. Int J Cancer 1997; 74: 31-34.
40. Saikku P. Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction. Eur Heart J 1993; 14 (Suppl 2): 62-65.
41. Saikku P, Leinonen M, Mattila K, et al. Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; ii: 983-985.
42. Leinonen M, Linnanmäki E, Mattila K, et al. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog 1990; 9: 67-73.
43. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Int Med 1992; 116: 273-278.
44. Thom DH, Wang SP, Grayston JT, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991; 11: 547-551.
45. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68-72.
46. Melnick SL, Shahar E, Folsom AR, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med 1993; 95: 499-504.
47. Davidson M, Kuo CC, Middaugh JP, et al. Confirmed previous infection with Chlamydia pneumoniae and its presence in early coronary atherosclerosis. Circulation 1998; 98: 628-633.
48. Mazzoli S, Tofani N, Fantini A, et al. Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J 1998; 135: 15-20.
49. Miyashita N, Toyota E, Sawayama T, et al. Association of chronic infection of Chlamydia pneumoniae and coronary heart disease in the Japanese. Int Med 1998; 37: 913-916.
50. Altman R, Rouvier J, Scazziota A, Absi RS, Gonzales C. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease. Clin Cardiol 1999; 22: 85-90.
51. Danesh J, Wong Y, Ward M, Muir J. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population-based study of coronary heart disease. Heart 1999; 81: 245-247.
52. Ridker PM, Kundsin RB, Stampfer J, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161-1164.
53. Strachan DP, Carrington D, Mendall MA, Ballam L, Morris J, Butland BK, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 1999; 318: 1035-1039.
54. Kark J, Leinonen M. Paltiel O, Saikku P. Chlamydia pneumoniae and acute myocardial infarction in Jerusalem. Int J Epidemiol 1997; 26: 730-738.
55. Linnanmäki E, Leinonen M, Mattila K, et al. Presence of Chlamydia pneumoniae specific antibodies in circulating immune complexes in coronary heart disease. Circulation 1993; 87: 1130-1134.
56. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. South Afr Med J 1992; 82: 158-160.
57. Taylor-Robinson D. Chlamydia pneumoniae in vascular tissue. Atherosclerosis 1998; 140 (Suppl 1): S21-24.
58. Daus H, Obzek C, Saage D, et al. Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation. Cardiology 1998; 90: 83-88.
59. Ouchi K, Fujii B, Kanamoto Y, Karita M, Shirai M, Nakazawa T. Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular disease. J Med Microbiol 1998; 47: 907-913.
60. Paterson DL, Hall J, Rasmussen SJ, Timms P. Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. Pathology 1998; 30: 169-172.
61. Petersen E, Boman J, Persson K, et al. Chlamydia pneumoniae in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1998; 15: 138-142.
62. Shor A, Phillips JI, Ong G, Thomas BJ, Taylor-Robinson D. Chlamydia pneumoniae in atheroma -consideration of criteria for causality. J Clin Pathol 1998; 51: 812-817.
63. Yamashita K, Ouchi K, Shirai M, Gondo T, Nakazawa T, Ito H. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 1998; 29: 773-778.
64. Bartels C, Maass M, Bein G, et al. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 1999; 99: 879-882.
65. Wong YK, Thomas M, Tsang V, Gallagher PJ, Ward ME. The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery. J Am Coll Cardiol 1999; 33: 52-156.
66. Bauriedel G, Hutter R, Welsch U, Lüderitz B Chamydia pneumoniae is more frequently found in coronary plaques of patients with unstable compared to stable angina. Vienna: Abstr ESC no. 1481, 1998.
67. Ramirez JAChlamydia pneumoniae/atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996; 125: 979-982.
68. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from carotid endarterectomy specimen. J Infect Dis 1997; 176: 292-295.
69. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31: 827-832.
70. Boman J, Söderberg S, Forsberg J, et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 1998; 178: 274-277.
71. Juvonen J, Laurila A, Alakärppä H, et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997; 25: 499-505.
72. Juvonen J, Laurila A, Juvonen T, et al. Detection of Chlamydia pneumoniae in human non-rheumatic stenotic aortic valves. J Am Coll Cardiol 1997; 29: 1054-1059.
73. Nyström-Rosander C, Thelin S, Hjelm E, Lindquist O, Påhlson C, Friman G. High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement. Scand J Infect Dis 1997; 29: 361-365.
74. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35: 48-52.
75. Laitinen K, Laurila A, Pyhälä L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aorta of rabbits. Infect Immun 1997; 65: 4832-4835.
76. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-636.
77. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997; 175: 883-890.
78. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-753.
79. Bachmeier K, Neu N, de la Maza LM, Paö S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999; 283: 1335-1339.
80. Stille W, Dittmann R, Justnubling G. Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae - a tentative hypothesis. Infection 1997; 25: 281-285.
81. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-1082.
82. Strandberg T, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-119.
83. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407.
84. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner BRoxis Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-407.
85. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes - The final report of the ROXIS study. Eur Heart J 1999; 20: 121-127.
86. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serologic evidence for Chlamydia pneumoniae infection. The azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-1547.
87. Sinisalo J, Mattila K, Nieminen MS, et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother 1998; 41: 85-92.
88. Grayston JT. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. Circulation 1998; 97: 1669-1670.
89. Grayston JT. Antibiotic treatment trials for secondary prevention of coronary artery disease events (editorial). Circulation 1999; 99: 1538-1539.
90. Gupta S. Chronic infection in the aetiology of atherosclerosis - focus on Chlamydia pneumoniae. Atherosclerosis 1999; 143: 1-6.
91. Noll G. Pathogenesis of atherosclerosis: a possible relation to infection. Atherosclerosis 1998; 140: S3-S9.
92. Leinonen M. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur Heart J 1993; 14 (Suppl 2): 57-61.
93. Kaukoranta-Tolvanen SS, Laitinen K, Saikku P, Leinonen M. Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathog 1994; 16: 313-319.
94. Godzik KL, O'Brien ER, Wang SK, Kuo CC. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995; 33: 2411-2414.
95. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614-1620.
96. Heinemann M, Susa M, Simnacher U, Marre R, Essig A. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Infect Immun 1996; 64: 4872-4875.
97. Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, Saikku P, Laitinen K. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microbial Pathog 1996; 21: 407-411.
98. Knoebel E, Vijayagopal P, Figueroa II JE, Martin DH. In vitro infection of smooth muscle cells by Chlamydia pneumoniae. Infect Immun 1997; 65: 503-506.
99. Airenne S, Surcel HM, Alakärppä H, et al. Chlamydia pneumoniae infection in human monocytes. Infect Immun 1999; 67: 1445-1449.
100. Coombes BK, Mahony JB. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell derived soluble factor(s). Infect Immun 1999; 67: 2909-2915.
101. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-259.
102. George J, Shoenfeld Y, Afek A, et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol 1999; 19: 505-510.
103. Morrison RP, Belland RJ, Lyng K, Caldwell HD. Chlamydial disease pathogenesis: the 57-kD chlamydial hypersensitivity antigen is a stress response protein. J Exp Med 1989; 170: 1271-1283.
104. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factorα and matrix metalloproteinase expression. Circulation 1998; 98: 300-307.
105. Kol A, Bourier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999; 103: 571-577.
106. Halme S, Saikku P, Surcel HM. Characterization of Chlamydia pneumoniae antigens using human T cell clones. Scand J Immunol 1997; 45: 378-384.
107. Mosorin M, Surcel HM, Laurila A, Saikku P, Juvonen T. Chlamydia pneumoniae reactive T lymphocytes in atherosclerotic plaque of carotid artery. In: Stephens RS et al, eds. Chlamydial Infections. Int Chlam Symp, San Francisco, USA, 1998: 423-425.
108. Patel P, Carrington D, Strachan DP, et al. Fibrinogen: a link between chronic infection and coronary heart disease. Lancet 1994; 343: 1634-1635.
109. Torgano G, Cosentini R, Mandelli C, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 1999; 99: 1555-1559.
110. Cook PJ, Lip GYH, Davies P, Beevers DG, Wise R, Honeyborne D. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension 1998; 31: 589-594.
111. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998; 177: 725-729.
112. Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 1998; 66: 5067-5072.
113. Karvonen M, Tuomilehto J, Pirkäniemi J, Naukkarinen A, Saikku P. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol 1994; 23: 1315-1321.
114. von Hertzen L, Surcel HM, Kaprio J, Koskenvuo M, Leinonen M, Saikku P. Immune responses to Chlamydia pneumoniae in twins in relation to gender and smoking. J Med Microbiol 1998; 47: 441-446.
115. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 2910-2913.
116. Murray LJ, O'Reilly DPJ, Ong GML, O'Neill C, Evans AE, Bamford KB. Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile. Heart 1999; 81: 239-244.
117. Leinonen M, Saikku P. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis. Am Heart J 1999; 138: S504-S506.
118. Kontula K, Vuorio A, Turtola H, Saikku P. Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in molecularly defined heterozygous familial hypercholesterolaemia. Lancet 1999; 354: 46-47.